Catalent gains on report it's likely to be granted EU approval for Novo Holdings deal

seekingalpha11-23

Carolina Rudah/iStock via Getty Images Catalent (NYSE:CTLT) rose 2% amid a report that the European Union's antitrust regulator will likely grant approval for its planned sale to Novo Holdings, the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2485293583?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2112991930/image_2112991930.jpg","is_english":true,"pubTime":"2024-11-23 00:10","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2485293583","market":"sh","top_or_hot":-1,"title":"Catalent gains on report it's likely to be granted EU approval for Novo Holdings deal","media":"seekingalpha","content":"<div>\n<p>Carolina Rudah/iStock via Getty Images Catalent (NYSE:CTLT) rose 2% amid a report that the European Union's antitrust regulator will likely grant approval for its planned sale to Novo Holdings, the ...</p>\n\n<a href=\"https://seekingalpha.com/news/4322149-catalent-gains-on-report-its-likely-to-be-granted-eu-approval-for-novo-holdings-deal\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Catalent gains on report it's likely to be granted EU approval for Novo Holdings deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCatalent gains on report it's likely to be granted EU approval for Novo Holdings deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-23 00:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4322149-catalent-gains-on-report-its-likely-to-be-granted-eu-approval-for-novo-holdings-deal><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Carolina Rudah/iStock via Getty Images Catalent (NYSE:CTLT) rose 2% amid a report that the European Union's antitrust regulator will likely grant approval for its planned sale to Novo Holdings, the ...</p>\n\n<a href=\"https://seekingalpha.com/news/4322149-catalent-gains-on-report-its-likely-to-be-granted-eu-approval-for-novo-holdings-deal\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://seekingalpha.com/news/4322149-catalent-gains-on-report-its-likely-to-be-granted-eu-approval-for-novo-holdings-deal","article_id":"2485293583","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2112991930/image_2112991930.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485293583","pubTimestamp":1732291818,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Carolina Rudah/iStock via Getty Images Catalent  rose 2% amid a report that the European Union's antitrust regulator will likely grant approval for its planned sale to Novo Holdings, the parent of Ozempic maker Novo Nordisk .  The European Commission is expected to give unconditional approval for the $16.5 billion purchase of Catalent  as the parties haven't been asked to attend a \"state of play\" meeting, according to an MLex report that circulated on Friday.  The EC has until Dec. 6 to decide if it will approve the combination or decide to start a more in-depth review.  Catalent  and Novo Nordisk Foundation received a request for more information from the Federal Trade Commission in May on their planned deal. In February, Catalent agreed to be acquired by Novo Holdings for $63.50 a share. Novo Holdings will then sell three Catalent manufacturing sites to Novo Nordisk , which should help increase production of the company’s hugely popular weight-loss drug, Wegovy.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4530":"医药外包概念","CTLT":"Catalent","BK4588":"碎股","BK4007":"制药"},"translate_title":"康泰伦特因报道Novo Holdings交易可能获得欧盟批准而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTLT":0.9},"content_text":"Carolina Rudah/iStock via Getty Images Catalent (NYSE:CTLT) rose 2% amid a report that the European Union's antitrust regulator will likely grant approval for its planned sale to Novo Holdings, the parent of Ozempic maker Novo Nordisk (NVO).  The European Commission is expected to give unconditional approval for the $16.5 billion purchase of Catalent (CTLT) as the parties haven't been asked to attend a \"state of play\" meeting, according to an MLex report that circulated on Friday.  The EC has until Dec. 6 to decide if it will approve the combination or decide to start a more in-depth review.  Catalent (CTLT) and Novo Nordisk Foundation received a request for more information from the Federal Trade Commission in May on their planned deal. In February, Catalent agreed to be acquired by Novo Holdings for $63.50 a share. Novo Holdings will then sell three Catalent manufacturing sites to Novo Nordisk (NVO), which should help increase production of the company’s hugely popular weight-loss drug, Wegovy.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485293583"}